Chemomab Therapeutics Ltd（CMMB）の株式分析CMMBChemomab Therapeutics Ltd

Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Chemomab Therapeutics Ltd (CMMB) is a good buy right now due to its recent price increase of 25.46% over the last 5 days and a strong RSI of 94.74, suggesting momentum. The company is also preparing for a Phase 3 trial for its lead drug candidate, which could significantly enhance its market position. However, the main risk is its negative net income, which was -2,165,000 USD in Q2 2026, indicating ongoing financial losses.